Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin

Lancet

Volumn 350, Issue 9092, 1997, Pages 1670-1673

  Hiramatsu, Keiichi ^a   Aritaka, Nanae ^a   Hanaki, Hideaki ^a   Kawasaki, Shiori ^a   Hosoda, Yasuyuki ^a   Hori, Satoshi ^a   Fukuchi, Yoshinosuke ^a   Kobayashi, Intetsu ^b  

^a JUNTENDO UNIVERSITY   (Japan)

^b MITSUBISHI CHEMICAL CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; CULTURE MEDIUM; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; SPUTUM CULTURE; STAPHYLOCOCCUS AUREUS;

EID: 0031566835     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)07324-8     Document Type: Article

References (24)

1. Aoki Y. Therapeutic strategy for MRSA infections. In: Ngeow Y-F, Hiramatsu K, eds. ASEAN-Japan seminar and workshop on hospital infection. Kuala Lumpur: University of Malaya Press, 1995: 47-56.
2. Shimada K, Kobayashi H, Sunagawa K, Inamatsu T, Yamaguchi K. Clinical summary of intravenous use of vancomycin hydrochloride for severe infection caused by methicillin-resistant Staphylococcus aureus. Jpn J Chemother 1995; 43: 1048-61.
3. Kaatz G, Seo SM, Dorman NJ, Lerner SA. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J Infect Dis 1990; 162: 103-08.
4. Brunet F, Vedel G, Dreyfus F, et al. Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicaemia who recovered after administration of vancomycin. Eur J Clin Microbiol Infect Dis 1994; 9: 145-47.
5. Mainardi J-L, Shlaes DM, Goering RV, Shlaes JH, Acar JF, Goldstein FW. Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus. J Infect Dis 1995; 171: 1646-50.
6. Shlaes DM, Shlaes DH. Teicoplanin selects for Staphylococcus aureus that is resistant to vancomycin. Clin Infect Dis 1995; 20: 1071-72.
7. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. 1997; 40: 135-36.
8. Hiramatsu K, Kondo N, Ito T. Genetic basis for molecular epidemiology of MRSA. J Infect Chemother 1996; 2: 117-29.
9. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, fourth edition: approved standard, M7-A4. Villanova, Pennsylvania: National Committee for Clinical Laboratory Standards, 1997.
10. Hiramatsu K. Molecular evolution of MRSA. Microbiol Immunol 1995; 39: 531-43.
11. Peterson LR, Shanholtzer CJ. Tests for bactericidal effects of antimicrobial agents: technical performance and clinical relevance. Clin Microbiol Rev 1997; 5: 420-32.
12. Berger-Bachi B, Strassle A, Kayser FH. Characterization of an isogenic set of methicillin-resistant and susceptible mutants of Staphylococcus aureus. Eur J Microbiol 1986; 5: 697-701.
13. Wada A, Ohta H, Kulthanan K, Hiramatsu K. Molecular cloning and mapping of 16S-23S rRNA gene complexes of Staphylococcus aureus. J Bacteriol 1993; 175: 7483-87.
14. Courvalin P. Resistance of enterococci to glycopeptides. Antimicrob Agents Chemother 1990; 34: 2291-96.
15. Niitsuma K, Saito M. Vancomycin inhalation therapy - a pharmacokinetic and clinical study of vancomycin. Antibiot Chemother 1996; 122: 123-35.
16. Torres JR, Sanders CV, Lewis AC. Vancomycin concentration in human tissues: preliminary report. J Antimicrob Chemother 1979; 5: 475-77.
17. Barber M. Naturally occurring methicillin-resistant staphylococci. J Gen Microbiol 1964; 35: 183-90.
18. Dyke KGH. Penicillinase production and intrinsic resistance to penicillins in methicillin-resistant cultures of Staphylococcus aureus. J Med Microbiol 1969; 2: 261-78.
19. Tanaka T, Okuzumi K, Iwamoto A, Hiramatsu K. A retrospective study of methicillin-resistant Staphylococcus aureus strains in Tokyo University Hospital. J Infect Chemother 1995; 1: 40-49.
20. Asada K, Inaba Y, Tateda-Suzuki E, Kuwahara-Arai K, Ito T, Hiramatsu K. Evolution and resistance expression of MRSA; evaluation of beta-lactam antibiotics against a set of isogenic strains with different types of phenotypic expression. Acta Biochimica Polanica 1995; 42: 517-24.
21. CDC. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep 1997; 46: 626-26, 635.
22. Hashimoto H, Inoue M, Hayashi I. A survey of Staphylococcus aureus for typing and drug-resistance in various areas of Japan during 1992 and 1993. Jpn J Antibiot 1994; 47: 618-26.
23. Daum RS, S. Dupta, R. Sabbagh, Milewski. WM. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility. J Infect Dis 1992; 166: 1066-72.
24. Sieradzki K, Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol 1997; 179: 2557-66.